Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 2
2010 1
2011 1
2013 1
2014 1
2015 2
2016 1
2017 4
2018 4
2019 7
2020 6
2021 10
2022 5
2023 6
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Results by year

Filters applied: . Clear all
Page 1
NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022.
Armstrong DK, Alvarez RD, Backes FJ, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, Chen LM, Chitiyo VC, Cristea M, DeRosa M, Eisenhauer EL, Gershenson DM, Gray HJ, Grisham R, Hakam A, Jain A, Karam A, Konecny GE, Leath CA III, Leiserowitz G, Liu J, Martin L, Matei D, McHale M, McLean K, Miller DS, Percac-Lima S, Remmenga SW, Schorge J, Stewart D, Thaker PH, Vargas R, Hendrickson AW, Werner TL, Zsiros E, Dwyer MA, Hang L. Armstrong DK, et al. Among authors: hendrickson aw. J Natl Compr Canc Netw. 2022 Sep;20(9):972-980. doi: 10.6004/jnccn.2022.0047. J Natl Compr Canc Netw. 2022. PMID: 36075393
Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study.
You B, Purdy C, Copeland LJ, Swisher EM, Bookman MA, Fleming G, Coleman R, Randall LM, Tewari KS, Monk BJ, Mannel RS, Walker JL, Cappuccini F, Cohn D, Muzaffar M, Mutch D, Wahner-Hendrickson A, Martin L, Colomban O, Burger RA. You B, et al. Among authors: wahner hendrickson a. J Clin Oncol. 2022 Dec 1;40(34):3965-3974. doi: 10.1200/JCO.22.01207. Epub 2022 Oct 17. J Clin Oncol. 2022. PMID: 36252167 Free PMC article. Clinical Trial.
Oncologic emergencies.
Behl D, Hendrickson AW, Moynihan TJ. Behl D, et al. Among authors: hendrickson aw. Crit Care Clin. 2010 Jan;26(1):181-205. doi: 10.1016/j.ccc.2009.09.004. Crit Care Clin. 2010. PMID: 19944281 Review.
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.
Moore KN, Secord AA, Geller MA, Miller DS, Cloven N, Fleming GF, Wahner Hendrickson AE, Azodi M, DiSilvestro P, Oza AM, Cristea M, Berek JS, Chan JK, Rimel BJ, Matei DE, Li Y, Sun K, Luptakova K, Matulonis UA, Monk BJ. Moore KN, et al. Among authors: wahner hendrickson ae. Lancet Oncol. 2019 May;20(5):636-648. doi: 10.1016/S1470-2045(19)30029-4. Epub 2019 Apr 1. Lancet Oncol. 2019. PMID: 30948273 Clinical Trial.
Current and Future Directions for PARP Inhibition.
Grudem M, Hendrickson AW. Grudem M, et al. Among authors: hendrickson aw. J Adv Pract Oncol. 2020 Apr;11(3):297-300. doi: 10.6004/jadpro.2020.11.3.16. Epub 2020 Apr 1. J Adv Pract Oncol. 2020. PMID: 33598329 Free PMC article.
Clinical Pearls in Oncology 2019.
Wahner-Hendrickson A, Bundrick JB. Wahner-Hendrickson A, et al. Dis Mon. 2019 Nov;65(11):100863. doi: 10.1016/j.disamonth.2019.06.005. Epub 2019 Jun 22. Dis Mon. 2019. PMID: 31239066 Review. No abstract available.
Doubling Down on BRCA-Mutated Cancer.
Wahner Hendrickson AE, Kaufmann SH, Swisher EM. Wahner Hendrickson AE, et al. Trends Cancer. 2017 Nov;3(11):743-744. doi: 10.1016/j.trecan.2017.09.005. Epub 2017 Sep 29. Trends Cancer. 2017. PMID: 29120748 Review.
A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283.
O'Cearbhaill RE, Miller A, Soslow RA, Lankes HA, DeLair D, Segura S, Chavan S, Zamarin D, DeBernardo R, Moore K, Moroney J, Shahin M, Thaker PH, Wahner-Hendrickson AE, Aghajanian C. O'Cearbhaill RE, et al. Among authors: wahner hendrickson ae. Gynecol Oncol. 2023 Sep;176:16-24. doi: 10.1016/j.ygyno.2023.06.021. Epub 2023 Jul 5. Gynecol Oncol. 2023. PMID: 37418832 Clinical Trial.
Cardiovascular Concerns in BRCA1 and BRCA2 Mutation Carriers.
Gast KC, Viscuse PV, Nowsheen S, Haddad TC, Mutter RW, Wahner Hendrickson AE, Couch FJ, Ruddy KJ. Gast KC, et al. Among authors: wahner hendrickson ae. Curr Treat Options Cardiovasc Med. 2018 Mar 1;20(2):18. doi: 10.1007/s11936-018-0609-z. Curr Treat Options Cardiovasc Med. 2018. PMID: 29497862 Review.
Carboplatin dosing in the treatment of ovarian cancer: An NRG oncology group study.
Praiss AM, Miller A, Smith J, Lichtman SM, Bookman M, Aghajanian C, Sabbatini P, Backes F, Cohn DE, Argenta P, Friedlander M, Goodheart MJ, Mutch DG, Gershenson DM, Tewari KS, Wenham RM, Wahner Hendrickson AE, Lee RB, Gray H, Secord AA, Van Le L, O'Cearbhaill RE. Praiss AM, et al. Among authors: wahner hendrickson ae. Gynecol Oncol. 2023 Jul;174:213-223. doi: 10.1016/j.ygyno.2023.05.013. Epub 2023 May 23. Gynecol Oncol. 2023. PMID: 37229879 Clinical Trial.
49 results